Guardant Health wins EU CE mark for Guardant360 CDx as camizestrant companion diagnostic in ER-positive breast cancer
GH•Guardant Health secured EU CE marking for Guardant360 CDx as a companion diagnostic for AstraZeneca’s camizestrant, targeting ESR1 mutations in ER-positive, HER2-negative advanced breast cancer. The clearance is Guardant’s 31st companion diagnostic approval.
1. EU diagnostic clearance
Guardant Health secured EU CE marking for Guardant360 CDx as a companion diagnostic for AstraZeneca’s camizestrant, also called ETCAMAH. The blood-based liquid biopsy targets ESR1 mutations in ER-positive, HER2-negative advanced breast cancer to guide treatment selection; Guardant said the clearance is its 31st companion diagnostic approval.
